LAS VEGAS--(BUSINESS WIRE)--Massive Bio, Inc., a global precision oncology and AI-enabled real-world data company, today announced at Ai4 2026 that it has made a strategic investment in Rivvi AI, Inc., an agentic AI infrastructure company for healthcare and life sciences. The transaction is Massive Bio’s first strategic investment in another AI company. It builds on the companies’ existing work across oncology trial programs and pairs capital with a shared plan to connect clinical intelligence,

WESTMINSTER, Colo.--(BUSINESS WIRE)-- #aiinfrastructure--Liqid® (www.liqid.com), the global leader in software-defined memory and GPU pooling infrastructure, today announced its role as a strategic technology partner in Abaco, the memory-centric computing system designed by Micron, a subcontractor to the U.S. Department of Energy’s (DOE) Pacific Northwest National Laboratory (PNNL). Liqid is providing the scale-up memory pool that allows PNNL to expose hundreds of terabytes of coherent active memory to data-intens

DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, today announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence from COVID-19 infection and mRNA vaccinations, linked to genomic instability, integration events, aggressive cancers, disabilities, and multi-system injuries. This work represents a formal research collaboration between Neo7Bioscience and Dr. Peter A. McCullough, M.D., M.P.H., Nicolas Hulscher,

DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, announced the launch of “Do It For Future You,” a new multichannel campaign designed to inspire individuals to take control of their health today to better safeguard their future. The campaign encourages discussions between individuals and their health providers about long-acting injectable HIV prevention and treatment options. The campaign uses one clear mess

MEMPHIS, Tenn.--(BUSINESS WIRE)--Kevin Burkhardt, FOX Sports’ lead NFL play-by-play announcer and MLB Studio Host, will become the 21st recipient of the coveted Pat Summerall Award, presented annually at the Legends for Charity® Dinner benefiting St. Jude Children’s Research Hospital®. The exclusive red carpet event will be held Feb. 11, 2027, at the NFL Headquarters Hotel, the JW Marriott Los Angeles L.A. Live, during Super Bowl LXI week. Legends for Charity hosts hundreds of supporters, broad

SANTA CLARA, Calif.--(BUSINESS WIRE)-- #MedicalInnovation--Exo (pronounced “echo”), the leader in AI-powered, accessible medical imaging, today announced expanded deployment options for Exo Iris® that give healthcare providers the freedom to choose the handheld ultrasound experience that best fits their clinical setting, infrastructure, and scale. The options extend Exo Iris from large, connected imaging programs to single operators and care teams working in disconnected environments. The expansion removes a key ad

LOS ANGELES--(BUSINESS WIRE)--Needed, the brand bringing practitioner-grade nutrition to women's supplements, today announced the launch of Needed Women's Creatine, a daily creatine monohydrate supplement where women's physiology drove every decision — from dose to digestion. Creatine builds strength, lean muscle, mental clarity, and cellular energy* — and it's one of the most studied compounds in human performance. But of the more than 4,500 studies published to date, just 4% have focused on wo

NEW YORK--(BUSINESS WIRE)--Claryx, a genomic intelligence company, came out of stealth today with $3.5 million in pre-seed funding led by Outlander VC. It's building an immune system for hospitals, one that catches transmission while it's happening, shows the infection prevention team where to intervene, and confirms afterward that it stopped. Claryx was founded by brothers Kurt and Dirk Hackenberger, and it began with their grandmother. In 2004 she went in for a routine procedure, developed C.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the introduction of the LOGIQ™ e family, featuring LOGIQ™ e Xi and LOGIQ™ e Si, two compact laptop ultrasound systems designed to help clinicians deliver simple, fast, and confident ultrasound imaging where it’s needed across care settings.ii Building on the legacy of LOGIQ e, the LOGIQ e family pairs a reliable console-level performance with a compact, intuitive design combining AI-powered featuresiii and workflow tools that support porta

DENVER--(BUSINESS WIRE)--PSC Partners Seeking a Cure (PSC Partners), a patient-led non-profit organization supporting education and research in primary sclerosing cholangitis (PSC), announced today it has been awarded funding through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI), for a project titled “Building Capacity to Engage in Patient-Led Comparative Clinical Effectiveness Research in Patients with PSC at Ris

MADISON, Wis.--(BUSINESS WIRE)--Archeus Technologies, a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers, today announced the reconstitution of its Advisory Board, appointing five leaders with deep expertise across clinical development, drug discovery, and biopharmaceutical leadership. “The Advisory Board has been rebuilt to reflect where Archeus is today — a company with two

TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, a global leader in AI-driven clinical trial simulation, today announced a $45 million Series B. The round was led by Qumra Capital, with support from additional investors, including Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures. Building on strong momentum and growing adoption of its solutions, QuantHealth

CHICAGO--(BUSINESS WIRE)--Sheridan announced its investment in Carolina Components Group, a provider of custom-engineered components for biopharmaceuticals manufacturing.

MEMPHIS, Tenn.--(BUSINESS WIRE)--Tau Kappa Epsilon (TKE) announced a $33 million commitment to St. Jude Children's Research Hospital®, the largest single philanthropic commitment ever made by a men's fraternity. The pledge comes as TKE celebrates fulfilling its 2019 announcement to raise $10 million in 10 years, accomplishing that goal three years ahead of schedule. The announcement was shared during the biennial TKE Conclave in New Orleans on July 31, where fraternity members and alumni gather

TORONTO--(BUSINESS WIRE)--Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) is pleased to announce the appointment of five additional advisors to the Company, as well as the grant of stock options to certain advisors and consultants of the Company. APPOINTMENT OF ADVISORS The Company has appointed the five individuals listed below as advisors to provide strategic advisory services to the Company. The advisors may receive compensation, including equity-based com

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical busin

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in Nature Medici

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Offers”) for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million. The terms and c

NORTH ANDOVER, Mass.--(BUSINESS WIRE)-- #Acquisition--Talica today announced the acquisition of Pure Clean Systems, a leading provider of high-purity cleaning, passivation, derouging, bioburden remediation, and electropolishing services. Pure Clean specializes in: Passivation and derouging of stainless steel high-purity systems and equipment Field services supporting biotech, pharma, data center, and other highly regulated facilities, including high-velocity flushing of liquid cooling and process piping syste

NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today advanced the direct U.S. commercial strategy for its Breast Acoustic CT™ Scanner with the appointment of Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West. Both executives joined QT Imaging in July 202

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies’ existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme® (pronounced “esteem”) collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zea

NEW YORK & SANTA BARBARA, Calif.--(BUSINESS WIRE)--Thesis Care, the AI-powered care team platform for scalable clinical capacity, and Cottage Health, the leading not-for-profit health system serving California's Central Coast, today announced a strategic innovation partnership. Through the collaboration, which marks the first health system partnership for Thesis, Cottage Health will deploy Thesis's AI care team agents to support high-impact clinical operations and care management workflows. Cot

LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scient

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dr

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 44,434 restricted stock units (“RSUs”) will be granted to 24 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist’s Amended and Res

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results. Quanterix will issue a press release regarding its second quarter 2026 financial results prior to the conference call on Monday, August 10, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.c

GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--Empower, a leading provider of retirement and wealth management solutions,1 today announced that it has been selected by the American Cancer Society as the plan administrator for its retirement plan. The plan serves approximately 7,000 American Cancer Society employees and includes about $475 million in assets under administration. The new contract began May 1, 2026. “We are proud the American Cancer Society chose Empower as their new financial service

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.

NEWTON, Mass.--(BUSINESS WIRE)--Satellite Biosciences, Inc. (Satellite Bio), a clinical-stage biotechnology company developing off-the-shelf liver therapies designed to restore liver function in patients with severe liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SB-101, an investigational medicine for the treatment of urea cycle disorders (UCDs). SB-101 is a first-in-class, off-the-shelf liver cell

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $50.7 million, representing 92% year-over-year growth and 15% sequential growth from the first quarter of 2026. The Company also advanced multiple regulatory and clinical programs across its immunotherapy pipeline while achieving its eighth consecutive quarter of

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. “Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics,” said Anand Parikh, Chief Executive Officer. “

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that it has been recognized as the Overall Winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group. The global program named BostonGene an Outstanding Organization, while simultaneously awarding top product honors for its multimodal AI platform. By integrating genomic, transcriptomic, immune profiling, imaging, and clinical data int

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2026. Second Quarter Business Highlights Completed its first full quarter under the Company's exclusive capitated agreement with a large national integrated delivery networ

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today reported results for the second quarter ended June 30, 2026. “I am pleased to report another outstanding quarter, driven once again by record revenue, substantial cash flow and impressive margin expansion,” said President and CEO Jennifer Scanlon. “As we monitor our business and the macro environment for the remainder of the year, we feel confident that our alignment with megatrend

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker’s President and CEO, commented: “We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieve

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Financial Results for Second Quarter 2026

CHARLOTTE, N.C.--(BUSINESS WIRE)--Enpro Inc. (NYSE: NPO) today announced its financial results for the second quarter ended June 30, 2026, and raises full-year guidance.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related

CHICAGO--(BUSINESS WIRE)--ADM (NYSE: ADM) today reported financial results for the quarter ended June 30, 2026 and updated its full-year 2026 outlook. 2Q26 Key Takeaways: Net earnings of $908 million, with adjusted net earnings1 of $895 million EPS2 of $1.87, with adjusted EPS1,2 of $1.84 2026 Outlook3: ADM now expects 2026 adjusted EPS1,2 of approximately $5.15 to $5.60, up from the prior adjusted EPS1,2 guidance range of $4.15 to $4.70 The updated outlook reflects expected year-over-year earn

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June 27, 2026. “We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team. Internal local currency sales growth accelerated compared to the first

BOSTON--(BUSINESS WIRE)--WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth c

SAN DIEGO--(BUSINESS WIRE)--LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,

CAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologis

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy’s Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.

LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis

NEW YORK--(BUSINESS WIRE)--Hospital for Special Surgery (HSS) once again leads the nation in orthopedic care, earning the No. 1 ranking in orthopedics for a record-setting 17th consecutive year and ranking No. 3 nationally in rheumatology by U.S. News & World Report 2026-2027 Best Hospitals: Specialty Rankings©. U.S. News evaluated nearly 4,500 hospitals in 14 specialties. Hospital performance was assessed based on various measures, including patient outcomes, level of nursing care, patient

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab. Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this agreement, the companies will advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, with Pathos assuming responsibility for the early clinical devel

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT® (sibeprenlimab-szsi) stabilizes estimated glomerular filtration rate (eGFR) returning kidney function decline to baseline physiologic rate over two years (24 months) in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Results presented durin

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company’s Board of Directors approved “inducement” grants to 95 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest

NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.9 million for its second quarter ended June 30, 2026, 21.4% higher than net income of $17.2 million for the second quarter of 2025. Net sales for the quarter ended June 30, 2026 were $174.0 million, 15.1%

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash. The close of the OEM transaction marks a pivotal milestone in Teleflex's transformation strategy, sharpening the Company's focus on the commercial excellence of its continuing businesses. The divestiture strengthens Teleflex's financial flexibi

BAD HOMBURG, Germany--(BUSINESS WIRE)-- #CommittedToLife--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize the biosimilar in the United States. The product was developed, manufactured, and submitted for approval by Dr. Reddy's

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.

CHATTANOOGA, Tenn. & COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ, Inc. (NYSE: IONQ), the world’s leading quantum platform company, and EPB, Chattanooga’s energy and communications solutions company, today announced plans for the Tennessee Quantum Communications Research Center. This will be the first dedicated next generation quantum communication research and development (R&D) innovation lab directly connected to a real-world network. “Interconnecting quantum computers at multiple locations a

LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) announced today it has entered into a definitive agreement to sell its medical business to Nordic Capital, an experienced healthcare investor with broad expertise and a deep understanding of the radiopharmaceutical industry and its value chain. The transaction, valued at up to $800 million, includes BWXT Medical and Kinectrics’ stable medical isotopes business. The sale will enable BWXT to concentrate resources and capital on

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter ended June 30, 2026. Second Quarter 2026 Revenue: $76.4 million, with revenue per active earning coach of $6,529 Independent active earning coaches of 11,700 Net loss of $3.1 million or $0.28 loss per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $169.8 million wit

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 115,600 common shares of the Company (the "Options") with effective grant dates of August 3, 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pilla

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2026, and provided business updates including progress of the global Pha

SAN DIEGO--(BUSINESS WIRE)--BioSurplus, one of the most recognized names in the life science equipment industry, has officially returned. For decades, BioSurplus helped organizations maximize the value of surplus laboratory assets while providing scientists and businesses with access to quality pre-owned equipment through one of the industry's most recognized online marketplaces. The return of the BioSurplus brand brings back a familiar resource for equipment buyers and sellers alike. Headquart

LAKELAND, Fla.--(BUSINESS WIRE)--Publix’s sales for the three months ended June 27, 2026 were $15.7 billion, a 1% increase from $15.6 billion in 2025. Publix’s sales for the six months ended June 27, 2026 were $31.9 billion, a 1.5% increase from $31.4 billion in 2025. The increase in sales for the three and six months ended June 27, 2026 compared to the three and six months ended June 28, 2025 was lower due to the impact of the Medicare maximum fair price (MFP) change effective January 1, 2026

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #ASPC2026--The Family Heart Foundation, a leading research, education and advocacy organization, today announced that Founder and Chief Executive Officer Katherine Wilemon has been named the 2026 Honorary Fellow Awardee by the American Society for Preventive Cardiology (ASPC), one of the nation's leading professional societies dedicated to advancing cardiovascular disease prevention. The award was presented during the ASPC 2026 Congress on Cardiovascular Disease Pre

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc

FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

KISSIMMEE, Fla.--(BUSINESS WIRE)-- #BattlefieldMedicine--PVP Labs, a clinical-stage biotechnology company advancing peptide-based therapeutics, today announced that research on Taphalgin® (Lumekefamide) has been selected for oral presentation at the 2026 Military Health System Research Symposium (MHSRS), a premier scientific forum focused on the unique medical needs of deployed Warfighters.Joseph Stauffer, D.O., MBA, FAPCR, Chief Medical Officer of PVP Labs, will present the company's research on Taphalgin as a promis

ORLANDO, Fla.--(BUSINESS WIRE)--Jackson PharmacyPros™, a pharmacy-exclusive staffing agency and workforce solutions provider, has been named to RXinsider's 2026 Pharmacy500, an annual recognition honoring the top pharmacy operations, supply chain businesses and associations that have made a significant impact on dispensing pharmacies across the United States over the past year. The 2026 listmakers are shaping the future of pharmacy through operational excellence, innovation and exceptional pati

LAKELAND, Fla.--(BUSINESS WIRE)--Eligible Medicare Plan D beneficiaries can have qualifying GLP-1 prescriptions filled at a Publix Pharmacy as part of the Medicare GLP-1 Bridge program. On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge program, a new initiative designed to expand access to innovative GLP-1 drugs for weight management. The program will remain available through Dec. 31, 2027. Covered Prescriptions The GLP-1 drugs currently availa

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons

BOCA RATON, Fla. & CHARLOTTE, N.C. & ATLANTA--(BUSINESS WIRE)--Massive Bio, Inc., a leader in AI-enabled oncology clinical trial matching and patient navigation, and QC Healthcare, LLC, a nationwide company focused on telehealth, clinical research, pharmacy services, artificial intelligence, healthcare analytics, and population health, today announced a strategic collaboration to fundamentally reshape how cancer patients access clinical trials, coordinated care, and telehealth support throughou

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Kiddom and the University of Florida Lastinger Center announced a research partnership studying if and how embedding professional learning at a teacher's precise point-of-need impacts instruction and student outcomes in middle school math.Kiddom built Florida's B.E.S.T.-aligned math curriculum to give teachers their core instructional materials, assessments, and insights in one coherent system. This partnership goes further, weaving Lastinger Center's instruct

ST. AUGUSTINE, Fla.--(BUSINESS WIRE)-- #MBC--Greenspace Health, a leader in Measurement-Based Care (MBC) technology for behavioral health, has launched Momentum, a new industry publication created to help behavioral health leaders navigate the growing shift toward outcomes-focused, value-based care. Featuring research, real-world case studies and practical implementation strategies, Momentum provides evidence-informed insights into the clinical, operational and economic impact of Measurement-Based Car

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu

PENSACOLA, Fla.--(BUSINESS WIRE)--Sugar Sands Publishing LLC today announced the formal constitution of the independent Cognitive Mode Operating System Standards Board (CMOS-SB) and launch of a governance framework for how AI systems interact with human emotion and cognition. THE GOVERNANCE GAP AI systems are increasingly being used in enterprise, health care, education and public infrastructure, where they can read emotional cues, respond to cognitive patterns and influence how people relate t

BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-L™ navigation instruments for use with the ION-L™ Lumbar Facet Fixation System. The system is engineered for compatibility with Medtronic's StealthStation™ navigation platform, enabling enhanced precision during posterior lumbar facet fusion proced

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf

TAMPA, Fla.--(BUSINESS WIRE)-- #biotech--Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Science by scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generatio

MIAMI & LOS ANGELES--(BUSINESS WIRE)-- #ClinicalAI--The Los Angeles County Department of Public Health (DPH) and OpenEvidence, an AI-powered clinical decision support platform, today announced a collaboration to help physicians quickly find official LA County Public Health resources when searching for clinical information. Under this new partnership, when physicians in LA County search the platform for selected public health topics, OpenEvidence will display related LA-specific messages from Public Health. T

BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital establishes The Foundation in the U.S., advancing a multigenerational philanthropic legacy focused on research, education and impact.

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne

MIAMI--(BUSINESS WIRE)--ReturnPro, the industry leader in returns management and reverse logistics, today announced findings from its new consumer study examining the effects of GLP-1 medications and how they are quietly reshaping what consumers are buying, returning, holding onto and wishing retailers would do differently to address their unique needs. The GLP-1 Effect report surveyed 500 U.S. adults currently taking, or who have taken within the past 12 months, a GLP-1 medication (Ozempic, We

JUPITER, Fla.--(BUSINESS WIRE)--Cancer Cell Diagnostics today announced the commercial launch of its CellSight™ DNA comprehensive genomic profiling test. This test is built on a fundamentally distinct source material from conventional liquid biopsy. Most blood-based cancer tests analyze cell-free circulating tumor DNA, the short, degraded fragments that tumors shed into the bloodstream. CCDx utilizes a different approach. The CellSight™ platform uses a proprietary, patent-pending enrichment met

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive’s portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi

TORONTO--(BUSINESS WIRE)-- #ARDS--Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health System Research Symposium (MHSRS), DOW's premier scientific meeting

JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, has opened its new 30,000 square foot state-of-the-art, vertically-integrated research and microgravity payload development facility in Georgetown, Indiana. The facility will serve as a global hub supporting accelerated demand as the company continues to expand its leadership in space-enabled research, development, and manufacturing with a focus on pharmaceutical/biot

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio partners with FOMAT, the largest U.S. Embedded Research Organization, to launch AI-powered cancer patient prescreening for clinical trials

MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon expands its seating line with Verro, a Medicare-coded custom cushion engineered for wheelchair users with complex postural needs.

MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will present at the Society of Robotic Surgery (SRS) Annual Meeting in Hollywood, Florida, July 22–26, 2026, on booth #325. At the meeting, interventional radiology leaders Prof. Dr. Sean Tutton, MD, Professor of Radiology and Orthopedics, and Dr. Govindarajan Narayanan, MD, FSIR, Professor of Radiology and Chief of Interventional Oncology and the first physician to treat a patient with Epion

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdomi

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced today the featured innovations in quality assurance (QA) for machine oversight and adaptive radiotherapy, as well as AI-assisted treatment planning, to be shown at the 2026 AAPM & COMP Annual Meeting, July 19–21 in Vancouver. Centered on the theme of Next-Gen Innovations for Next-Level Physics, the Sun Nuclear exhibit reflects a focus on smart, practical tools that support medical physics teams to operate wit

MIAMI & BOSTON--(BUSINESS WIRE)-- #medicalAI--Boston Children's Hospital, one of the nation's top pediatric hospitals, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a multi-year collaboration to examine how clinicians' real-world use of AI tools at the point of care relates to practice patterns and delivery of care. OpenEvidence has seen broad adoption in clinical settings, yet little is known about how that adoption relates to clinical practice patterns at a p

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2026. Financial Results Revenue The revenues for the second quarter of fiscal 2026 were $7.8 million compared to $7.9 million for the second quarter of fiscal 2025, a 2% decrease. The revenues for the second quarter of fiscal 2026 consisted of $7.7

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--The Paley Orthopedic & Spine Institute (Paley Institute), the world's leading center for stature surgery, achieves another historic milestone with the first completed stature surgery utilizing the latest FDA-approved PRECICE Max (PMAX) nail. As the exclusive global launch center for the technology, Paley Institute continues to lead the evolution of modern stature surgery – an advanced application of limb lengthening science pioneered over decades of o

TAMPA, Fla. & RAROTONGA, Cook Islands--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC"), which is building a responsible supply of critical minerals and rare earth elements through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), today highlighted Moana Minerals Ltd.'s ("Moana Minerals" or "MML") completion of a high-definition autonomous underwater vehicle seafloor survey within its Exploration License 3 (“EL3”) area in the Cook Islands Exclusive Eco

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit’s Phase III Ri-CoDIFy study for the tre

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a technology company that uses artificial intelligence to help cancer patients identify clinical trials for which they may be eligible, today announced a new partnership with Sequence Me Now (SMN), a nonprofit patient advocacy organization dedicated to helping cancer patients access genomic sequencing and personalized medicine. Through the partnership, Massive Bio is featured on the "Find a Trial" page of Sequence Me Now's website, the fourth step

MIAMI & NEW YORK--(BUSINESS WIRE)-- #MedicalAI--OpenEvidence, a medical AI and clinical decision support tool for U.S. clinicians, today announced a collaboration with NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, to deploy OpenEvidence across all hospitals and care sites throughout the Greater New York region. This enterprise-scale collaboration will place trusted, evidence-based clinical AI in the hands o

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.

MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principal Investigator at Merck Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, to serve in strategic advisory roles at Space Microgravity Development LLC (SpaceMD), Redwire’s venture company focuse

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the next phase of its growth strategy, marked by an expanding portfolio of therapies, growing commercialization capabilities, and continued investment in its pharmaceutical platform. The milestone reflects Pangea's evolution into a scalable pharmaceutical organization focused on identifyi

TAMPA, Fla. & DALLAS--(BUSINESS WIRE)--Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010

MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from preclinical research through clinical development. Mr. Snitkovsky is recognized for his strategic leadership, operational rigor, and ability to unite cross‑functional and globa

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Coral Connect, LLC announced it has acquired AdvisorWoRx, LLC, the strategic healthcare consulting firm founded and led by Edie Gigot, MSN-RN, MBA. Coral is a specialty infusion enablement platform that helps healthcare operators improve their purchasing decisions, operate leaner, and get reimbursed more across every site of care. Gigot joins Coral's executive leadership team as President of Infusion Services, leading the company's clinical operations, phar

TAMPA, Fla.--(BUSINESS WIRE)-- #AOSSM--OSSIO Inc., a fast-growing medical technology platform company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants, today confirmed its slate of activities and announcements planned for the upcoming American Orthopaedic Society for Sports Medicine (AOSSM) 2026 annual meeting at the Seattle Convention Center July 8–11. Update on study of KneeBar Procedure. Interim results from the multicenter, 50-patient clinical study of the c

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro

SINGAPORE--(BUSINESS WIRE)--MuseCell Innovations launches world's only clinically validated stem cell platform in the US for disease treatment, performance, and aesthetics.

MIAMI--(BUSINESS WIRE)--Men’s Health Month serves as an important reminder that sexual wellness is a fundamental component of overall well-being, yet it is often overlooked in conversations about men’s health. While discussions frequently focus on fitness, mental health, and preventive care, sexual health plays an equally vital role in a man’s quality of life, confidence, and relationships. Prioritizing protection is an important part of maintaining sexual wellness, empowering men to take an ac

WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced a new standalone prior authorization platform built for independent practices, regional health centers and specialty clinics. The denial reduction tool analyzes clinical documentation against applicable payer policies before submission and returns a real-time score, identifying gaps in the record that may trigger a denial while reducing time spent on preparation. It also featur

TALLAHASSEE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts

MIAMI & BOSTON--(BUSINESS WIRE)--The Journal of Medical Insight’s peer-reviewed surgical video library is now part of OpenEvidence.

TAMPA, Fla.--(BUSINESS WIRE)--ReliaQuest today announced a $1.5 million investment to expand AI cybersecurity research and education at the University of South Florida’s College of Artificial Intelligence, Cybersecurity and Computing. The gift will establish the college’s first-ever endowed professorship and create a new study track within the ReliaQuest Labs program focused on artificial intelligence-supported software engineering. “Cybersecurity is the greatest technical challenge of our gene

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.

TAMPA, Fla.--(BUSINESS WIRE)-- #medicaldevice--In striking an exclusive distribution agreement with OrthoPediatrics Corp. announced today, OSSIO Inc. expands access to its revolutionary orthopedic fixation technology — bio-integrative, metal-free OSSIOfiber® implants — to the approximately 400 U.S. children’s hospitals and care facilities whose orthopedic surgeons treat most pediatric patients admitted with bone fractures and skeletal deformities. "It’s not often that kids need implants for broken bones, since

TAMPA, Fla.--(BUSINESS WIRE)--Today, American Ocean Minerals Corporation (AOMC) announced the successful completion of Expedition 7, a research campaign designed to support the environmental baseline studies required for future deep-sea mineral exploration and development activities in the Cook Islands. Expedition 7 was conducted over approximately three weeks aboard the MV Anuanua Moana, a proprietary research vessel advancing critical deep-sea environmental and exploration programs across its

BOCA RATON, Fla.--(BUSINESS WIRE)--ModMed®, a leading provider of software and services to specialty medical practices, today announced that its AI-powered clinical documentation solution, ModMed Scribe 2.0, has been used in more than 1,000,000 patient visits. The explosive growth was driven by a 300% growth rate in usage that climbed from 240,000 visits in March to over 1 million just three months later. ModMed Scribe delivers immediate and dramatic results for clinicians across the specialtie

MIAMI & HOUSTON--(BUSINESS WIRE)--The Society for Neuro-Oncology (SNO), the world's largest multidisciplinary organization dedicated to advancing research, education, and clinical care for patients with brain and spinal cord tumors, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a landmark partnership, designating OpenEvidence as SNO's official generative AI partner. As part of the collaboration, SNO will embed OpenEvidence across its member-facing

TAMPA, Fla.--(BUSINESS WIRE)-- #Akumin--Akumin Inc. (“Akumin” or the “Company”), a leading provider of diagnostic imaging and oncology solutions, has announced the formation of Mobile Healthcare Innovations (MHI), a joint venture partnership with Wisconsin based manufacturer CGS Premier, to engineer, assemble and deploy Akumin AXIS® relocatable clinics to meet growing U.S. demand. Leaders cut the ribbon on a new 85,400-square-foot facility in New Berlin, Wisconsin, purposefully built in size and structur

PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--Eligible health plan members can now use the NationsBenefits® Flex Card at Sam’s Club to simplify grocery, OTC, and health and wellness purchases.

BOCA RATON, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--New study in Optometry and Vision Science validates Bruno Vision Care's Deseyne® EDOF lens technology, expanding options for presbyopia correction.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA’s Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando,

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. “We are pleased to welcome a talented and experienced financial executive of John’s caliber to CONMED,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “John brings deep healthcare and

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

MIAMI, GENEVA & SÃO PAULO--(BUSINESS WIRE)-- #Brazil--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute welcome the open letter issued by President Luiz Inácio Lula da Silva of Brazil and World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus on the occasion of the G7 Summit, calling on the leaders of the G7, G20, BRICS, and all nations to finish the Pathogen Access and Benefit-Sharing (PABS) annex of the WHO Pandemic Agreement. AHF particularly commends t

MINNEAPOLIS--(BUSINESS WIRE)--HUMANETICS CORPORATION SELECTED FOR ORAL PRESENTATION AT 2026 MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM

BOSTON & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #BIO2026--The LHS Fifteen-Slide Presentation® returns to BIO 2026 with new AI-era strategies for building investor-ready biotech stories.

JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo

TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent’s network.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced FDA clearance of its ION-L™ Lumbar Facet Fixation System. ION-L™, part of SurGenTec's facet fixation platform, is indicated for the treatment of patients with degenerative disc disease (DDD) from L3 to S1 in skeletally mature patients who have failed conservative care. This clearance is supported by compelling long-term clinical evidenc

TORONTO & NEW YORK--(BUSINESS WIRE)-- #AppliedSciences--Researchers at Klick Labs are launching a series of clinical studies with Mayo Clinic in Florida exploring the use of novel vocal biomarkers.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. The investment includes construction of a new, state-of-the-art distribution facility, alongside advanced manufacturing and packaging technologies to exp

DEERFIELD, Ill.--(BUSINESS WIRE)--As millions of fans travel to FIFA World Cup 2026™ matches in the U.S. this summer, Walgreens is making it easier to stay prepared, energized and healthy with convenient access to game-day essentials and trusted pharmacy services. Whether heading to the stadium or wrapping up a late match, Walgreens offers fans in Miami a one-stop destination for official licensed products of the FIFA World Cup 26™ and necessities like water, snacks, sunscreen, over-the-counter

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Paysafe (NYSE: PSFE), a global payments platform, is taking its technology to the heart of America’s biggest soccer summer, fueling a 39-day, 15,000-mile streamed road trip powered by viral creators Woody & Kleiny. Known as the ‘In A State’ tour, this record-breaking journey streams live on Kick and TikTok from June 11, as Woody & Kleiny tear through major cities including Los Angeles, Arlington, Boston and East Rutherford, engaging soccer fans and s

MIAMI--(BUSINESS WIRE)--ERMA Systems, the AI-powered Medical, Legal, and Regulatory (MLR) review platform built specifically for life sciences organizations, today announced its inclusion on the 2026 Agency Partners Power List published by MM+M, one of the healthcare industry's leading publications. The recognition highlights organizations shaping the future of healthcare commercialization and innovation. ERMA was recognized in the AI Health Platforms category for its transformative approach to

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.3 Benefits of TECNIS PureSee IOL: Range of vision: Excellent distance and intermediate vision with some near vision3* Low level of bothersome visual symptoms: 97% of p

MIAMI--(BUSINESS WIRE)--DermaSensor, a health technology company transforming skin cancer detection with AI-powered technology, today announced it has received Class IIb CE Mark for the DermaSensor device, enabling commercialization across the European Economic Area (EEA) and marking the beginning of the company’s global expansion strategy. The CE Mark demonstrates that DermaSensor meets European Union standards for safety, health, and environmental protection and paves the way for broader inte

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c

MIAMI & SAN FRANCISCO--(BUSINESS WIRE)-- #ClinicalAI--The American Academy of Ophthalmology, the world’s largest association of eye physicians and surgeons, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a strategic partnership to integrate the Academy’s Preferred Practice Patterns® and Ophthalmic Technology Assessments directly into the OpenEvidence platform. The partnership makes the Academy’s authoritative ophthalmology guidance available alongside the br

STOUGHTON, Mass. & JACKSONVILLE, Fla.--(BUSINESS WIRE)--Shields Health Solutions Brings Integrated Specialty Pharmacy Services to Baptist Health in Jacksonville

COCOA BEACH, Fla.--(BUSINESS WIRE)--Alesis LLC today announced the addition of three new joint venture locations to the Alesis Apnea Network in a single week: the TMJ & Sleep Therapy Centre of Chicago in St. Charles, Illinois; Alpha Omega Dental Center in Marquette, Michigan; and South Florida Food Allergy Center in Boca Raton, Florida. Together, the additions bring the Alesis Apnea Network to a total of five joint venture locations across five states, connecting patients who suffer from ob

LOUISVILLE, Ky.--(BUSINESS WIRE)--This past Saturday, Republic Bank & Trust Company (“Republic” or the “Bank”) hosted its sixth annual Juneteenth celebration at the Republic Bank Foundation YMCA, bringing together community members for a day centered on wellness, education, and culture. The event created a vibrant, welcoming atmosphere where attendees danced, explored local vendor booths, and enjoyed food from businesses proudly operated by Black and women entrepreneurs. “At Republic Bank,

ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance and Full Commercial Launch of Its Lux Expandable Interbody Fusion System

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio

BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)-- #DrivenbyPurpose--Vycellix to attend key upcoming investor & partnering events to share progress reports for its allogeneic cancer cell therapy platforms and products.

MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon raises $5.75M led by Enable Ventures to expand smart seating solutions for wheelchair users, aviation and beyond.

WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced it has joined the Centers for Medicare and Medicaid Services (CMS) Electronic Prior Authorization Acceleration initiative as a Friend of the Ecosystem. Launched through the CMS Health Tech Ecosystem, it brings together health systems, payers, electronic health record developers, and technology partners to address the workflow, technical, and operational challenges slowing adopt

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. This can help clinicians reduce treatment planning time, enabling them to focus on delivering more timely and personalized care for patients. The FDA clearance includes a Predetermined Change Control

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting

NEW YORK--(BUSINESS WIRE)--Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today, the Company presented results from several clinical and preclinical studies that support the initiation of Phase 3 studies of elismetrep, a novel TRPM8 channel blocker. Elismetrep is a potentially new approach for migraine and the only agent known to be in late-stage deve

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and Optellum, the leader in AI-enabled lung cancer diagnosis and the developer of the world’s first FDA-cleared clinical decision support software for early-stage lung cancer, today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung cancer (NSCLC). The collaboratio

NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Riley J. Williams III, MD, as Venue Medical Officer (VMO) for the 2026 World Cup. The New York / New Jersey area will host matches, including the final, taking place in East Rutherford, New Jersey at MetLife Stadium. In this role, Dr. Williams, Chief of the HSS Sports Medicine Institute, Medical D

HOLLYWOOD, Fla.--(BUSINESS WIRE)--STARLIMS, a global leader in enterprise laboratory informatics software, today announced the appointment of Max Schultz as Chief Executive Officer. This leadership transition comes at a time of growth for STARLIMS, with the company accelerating product innovation, expanding its portfolio through strategic acquisitions, and delivering agentic capabilities for enterprise laboratories. As a seasoned enterprise software executive, Schultz brings a strong track reco

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical announces FDA clearance and full commercial launch for its Riva Posterior Fixation System.

BOSTON & TAMPA, Fla.--(BUSINESS WIRE)--eternalHealth, a Medicare Advantage plan serving Medicare beneficiaries in Massachusetts and Arizona, today announced an integrated partnership with Zynix AI, a healthcare AI platform built to operationalize care management, patient engagement, and quality improvement at scale, and nirvanaHealth, a cloud-native enterprise platform supporting pharmacy benefit management, claims adjudication, and centralized healthcare data infrastructure. Since January 1, 2

GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a seminal study co-authored by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Annals of Neurology reveals a positive alpha-synuclein (α-synuclein) seed amplification assay (SAA) and the automated imaging differentiation for parkinsonism (AIDP) provide unique information key to understanding Parkinson’s diseas

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program. “Research and clinical evidence continue to be at the core of

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, entitle

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Thousands of Floridians living with HIV will keep the medication that keeps them alive, after the Florida Legislature today passed a state budget that reverses this year's cuts to the AIDS Drug Assistance Program (ADAP). The budget returns eligibility to 400 percent of the federal poverty level, brings back the medications the Department of Health had dropped, including Biktarvy, funds the program with $75 million, and adds independent oversight. "This is wha

BOCA RATON, Fla.--(BUSINESS WIRE)-- #CervicalSpine--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-C™ navigation instruments for use with the ION-C™ posterior cervical facet fixation implant. The system is engineered for comp

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced a new partnership with TOUCH, The Black Breast Cancer Alliance (TOUCH BBCA), a breast cancer patient advocacy organization, and Navigating Trials, a clinical trial navigation platform serving patients across all cancer types. Through this collaboration, Massive Bio's AI-powered trial matching will be made available directly within both organizations' digital platforms, giving their patient commu

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo

ROCHESTER, Minn.--(BUSINESS WIRE)--Inspirity Health Partners (IHP) has entered into a strategic, multi-year agreement with Tallahassee Memorial HealthCare (TMH) to advance and integrate TMH’s supply chain capabilities through a collaborative, high-performance partnership model. With a well-established category management structure, disciplined operational processes and strong clinical engagement, TMH joins Inspirity from a position of strength. Through this new collaboration, TMH will expand it

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences’ Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentat

COCOA BEACH, Fla. & SEATTLE--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device, today announced a joint venture partnership with Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA -- a dual board-certified sleep dentist with offices in Seattle and Renton, Washington. Dr. Fisher is the first sleep dentist in the Seattle area to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP therapy. Th

MIAMI--(BUSINESS WIRE)-- #ASCO--Today, OpenEvidence, the most widely used medical knowledge platform, announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model. As a part of OpenEvidence's commitment to creating advanced AI models for medical specialties, the company has extended their oncology model to include the ASCO Guidelines. ASCO Guidelines will now appear within OpenEvidence answers, accompanied by peer-reviewed evidence, precise citations, and a direct li

MOUNT ROYAL, N.J.--(BUSINESS WIRE)-- #AHSAM--Leading researchers and clinicians gather June 4–7 for the AHS 68th Annual Scientific Meeting, the premier scientific conference in headache medicine.

ORLANDO, Fla.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today announced the start of full operations of its newest CenterWell Pharmacy® mail order distribution center, in Orlando, Florida. The $83 million, state-of-the-art facility bolsters capacity for prescription medication delivery across Florida and the country and reinforces Humana’s longstanding commitment to providing members and patients across the Sunshine State with a simp

CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago. The findings in the poster presentation demonstrate the value of Arima’s Hi-C sequencing-based approach to fusion and rearrangement detection, available clinically through t

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare

PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits®, the leading healthcare fintech and outcomes platform, today announces its selection by Sam’s Club to manage all Sam’s Club hearing centers across the U.S. This collaboration integrates world-class technology and clinical expertise from NationsHearing® directly into the club to deliver advanced hearing care and outcomes-focused wellness care. These services are designed to improve overall well-being through a modern, member-centric experience

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that management will participate in the Goldman Sachs Healthcare Conference from June 8-10 in Miami, FL.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET. A live webcast o

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes’ proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r

MIAMI--(BUSINESS WIRE)-- #clinicalai--OpenEvidence, the most widely used medical AI platform among U.S. physicians, today launched Voice Mode, the first native speech-to-speech medical AI interface. With Voice Mode, OpenEvidence becomes the first multimodal medical AI offering a hands-free way for clinicians to ask questions aloud, and hear cited answers read back, on the same peer-reviewed evidence base. The feature is live in the OpenEvidence web and mobile apps and is free for all users. Physicians reach

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a leader in AI-enabled patient recruitment and oncology solutions, today announced expanded access to oncology clinical trials through AI-powered patient pre-screening leveraging a privacy-preserving clinical data collaboration infrastructure. The initiative enables Massive Bio's artificial intelligence-driven clinical trial matching capabilities to operate securely on sensitive cancer data within BeeKeeperAI’s privacy enhancing platform, EscrowAI

MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving both an oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29 in Miami, Florida. The presentations will highlight Forvisirvat (SP-624), Arrivo’s first-in-class oral activator of the SIRT6 enzyme, currently in a Phase 2b/3 study for major depressive disorder, with data read out expected later this year. Prior Phase 2 data demonstrated a signal of efficacy

BOSTON--(BUSINESS WIRE)--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem.

MIAMI--(BUSINESS WIRE)--QAD | Redzone, the company delivering the leading manufacturing platform, powered by Agentic AI that executes work and decisions across the business, from the shop floor to the top floor, announced the release of A CFO’s Pragmatic Guide to AI in Mid-Market Manufacturing, a new executive white paper designed to help manufacturing leaders navigate the growing wave of AI investment with greater operational and financial discipline. The paper argues that while AI activity ac

TAMPA, Fla.--(BUSINESS WIRE)-- #340b--CAN Community Health, the nation’s leading resource in comprehensive health services, today announced a new business entity dedicated to helping health systems, hospitals, physician practices, and specialty clinics unlock the full potential of high-cost specialty therapies while improving patient access, operational efficiency, and long-term sustainability. Healx Solutions launches to support healthcare organizations navigating the growing complexity of specialty m

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes’ ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using lipid nanoparticle delivery to power the next wave of mRNA and gene correction therapeutics, today announced the presentation of clinical data from its RCT1100 PCD inhaled mRNA program at the American Thoracic Society (ATS) 2026 International Conference, held May 15-20, 2026, at the Orange County Convention Center in Orlando, FL. The data represent the first clinical evidence of biological

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: “Rel

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, F

CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the innovative aerospace company, owner and operator of the world's largest fleet of commercial supersonic aircraft, is pleased to report its financial results for the first quarter of fiscal 2026 for the period ended March 31, 2026. To review the full financial results, please view the Company’s recent 10-Q filing with the U.S. Securities and Exchange Commission at www.sec.g

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data from the first 48 weeks of the ongoing OL treatment period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. IMPALA-2 is the longe

PARIS--(BUSINESS WIRE)-- #cancer--Sensome announces positive first-in-human results for its in situ tumor detection technology for lung cancer.

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--As healthcare providers and health plans grapple with growing continuous glucose monitoring (CGM) adoption and persistent gaps in diabetes outcomes alongside growing chronic care costs, a new research-driven poster from CCS is challenging the assumption that simply being prescribed a CGM device is enough. While CGM initiation is often associated with early improvements in glycemic control, new research from CCS suggests those improvements are not consisten

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the data presented

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--As West Palm Beach rapidly emerges as the next model American city, Visium, a leader in Far-UVC environmental control technology, is playing a central role in shaping how modern buildings support health, wellness, and productivity. Headquartered in the heart of CityPlace, Visium is deeply embedded within the transformation led by Related Ross, one of the country’s most influential real estate developers. With over $10 billion committed to Palm Beach Count

MORRISVILLE, N.C.--(BUSINESS WIRE)--Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, today announced late-breaking Phase 1 data for its inhaled drug candidate ALX1, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida. The data demonstrates that ALX1, a first-in-class nitric oxide prodrug designed for targeted delivery to the lungs, was well tolerated without safety concerns

MIAMI--(BUSINESS WIRE)-- #ai--Entanglement, Inc., a next-generation computing and AI company advancing quantum logic, optimization, and artificial intelligence, today announced that its Chief Research Scientist, Dr. Fred Glover, has been ranked #30 worldwide and #22 in the United States in Research.com’s 2026 Best Mathematics Scientists ranking. The fifth annual edition of the ranking evaluates more than 3,500 leading researchers across the mathematical sciences using the discipline-specific D-index,

LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, today announced the launch of the EB-710US Ultrasound Bronchoscope, a novel next-generation endobronchial ultrasound (EBUS) solution designed to streamline workflow and enhance imaging performance for pulmonologists and healthcare systems. The new scope will be demonstrated at booth #1815 at the American Thoracic Society Conference (ATS), May 18-20 in

NOTTINGHAM, England--(BUSINESS WIRE)-- #AI--Ideagen, a global software company with its US headquarters in Fort Lauderdale, has been unveiled as the Official AI Technology Principal Partner of Glasgow 2026, Presenting Partner for Netball and an Official Partner for Team Scotland, becoming one of the primary sponsors of the UK’s biggest sporting event this year. Launched in 2009, Ideagen technology sits at the heart of quality, safety and compliance in the world's most regulated and high-compliance in

PLANO, Texas--(BUSINESS WIRE)-- #Biotech--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that members of its management team will participate in three upcoming investor conferences this summer. Secretome is scheduled to attend the following conferences: Jefferies Global Healthcare Conference June 2 – 4, 2026 New York, New York Oppenheimer CNS & Neuro-Muscular Summi

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A w

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, the global leader in AI-driven clinical trial matching for cancer patients, and Just Worldwide, a leading global fieldwork and market research provider specializing in healthcare, biotech, life sciences, and pharmaceutical sectors, today announced a strategic partnership focused on connecting cancer patients to clinical trial opportunities through patient communities, advocacy groups, and patient organizations. Under the agreement, Just Worldwide

ALTAMONTE SPRINGS, Fla.--(BUSINESS WIRE)-- #BiotechInnovation--In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment. This marks the first time umbilical cord blood stem cells have been evaluated for a treatment not related to transplantation and regeneration of the recipient’s bone marrow to generate new blood cells. This early success could lead to numerous other trials for a wide range of trea

MIAMI--(BUSINESS WIRE)--OrganaBio, LLC ("OrganaBio"), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization. Newly formed OrganaBio subsidiary Excellos Labs, LLC (“Excellos Labs”) will be responsible for San Diego operations going forward. The acquisition creates a mor

BOSTON & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #DigitalCommunications--LaVoie announces trademark renewal for its LHS Immersion® and The LHS Fifteen-Slide Presentation® communications methodologies

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the appointment of Gordon Van Ummersen to its board of directors. “I am pleased to join Catalyst OrthoScience’s board at this important stage of the company’s evolution,” said Van Ummersen. “Catalyst is an exciting shoulder-focused company that has built a compelling platform focused o

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida’s lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Under the agreement, Catalent will also be granted exclusive manu

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations T

ORLANDO, Fla.--(BUSINESS WIRE)--OutcomeRx Insurance Management Services, LLC today announced the launch of CGT Solutions Stop-Loss, a stand-alone medical stop-loss insurance product that reimburses covered expenses on qualified claims for Gene and CAR T-cell therapies for group health plans and their coordinating Stop-Loss carrier. This innovative solution, in addition to reimbursement for certain FDA approved Prescription Drugs, uniquely reimburses administration of the Prescription Drug and t

CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs today announced the launch of a new API integration platform designed to help pharmacy benefit managers (PBMs), third-party administrators (TPAs), and healthcare organizations streamline prescription sourcing and specialty medication management within their existing workflows. The platform connects pricing, patient onboarding, regulatory documentation, shipment tracking, and claims reporting into a single integration, reducing the need for manual proc

ORLANDO, Fla.--(BUSINESS WIRE)--At this year’s Pediatric Orthopedic Society of North America (POSNA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies evaluating outcomes for three of the most common anterior cruciate ligament (ACL) reconstruction techniques designed to protect open growth plates in young patients who are still growing. The findings highlight the importance of using imaging before and after surgery to accurately identify and monitor alignme

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 20

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient or

COCOA BEACH, Fla. & MOORESVILLE, N.C.--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device and headquartered on Florida’s Space Coast in Cocoa Beach, today announced a joint venture partnership with Lake Norman Pulmonary & Sleep in Mooresville, North Carolina — making it the first sleep medicine practice in the Piedmont region to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP

MIAMI & ROSEMONT, Ill.--(BUSINESS WIRE)-- #MedicalAI--Today, the Society of Surgical Oncology (SSO), a global professional society for cancer surgeons, and OpenEvidence, the most widely used medical knowledge platform, announced a strategic partnership to strengthen access to the most trusted surgical oncology evidence at the point of care while building a foundation for innovative collaborations to support surgeons and all physicians taking care of patients with cancer. Together, SSO and OpenEvidence will

MUMBAI, India & ORLANDO, Fla.--(BUSINESS WIRE)---- $LTM #AI--LTM today announced the launch of the LTM Business Orchestration platform to orchestrate intelligent and autonomous enterprise operations across SAP.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve

MIAMI--(BUSINESS WIRE)-- #Coolibar--Coolibar, the world’s leading UPF 50+ sun protection apparel brand, is continuing its partnership with skin cancer survivor and advocate Dayanara Torres and the Melanoma Research Foundation (MRF) for Skin Cancer Awareness Month this May. The 2026 campaign brings a more intimate and elevated creative direction to Coolibar’s sun safety message, using emotional storytelling to encourage prevention, protection, and early detection. Together, the partners aim to reach communi

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced that SkinCure Oncology and Sensus Healthcare have amicably resolved their dispute and are moving forward constructively with a shared commitment to patient care and clinical excellence. In March 2026, Sensus Healthcare filed a lawsuit in the Circuit Court for the Fifteenth Judicial Cir

BOCA RATON, Fla.--(BUSINESS WIRE)-- #ContactLenses--Bruno Vision Care's FDA-cleared Deseyne® Extended Depth of Focus daily disposable contact lens for presbyopia wins 2026 MedTech Breakthrough Award.

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. Excluding sales to the Company’s historically largest customer, rev

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that the Catalyst Fracture System received the “Medical Device Engineering Breakthrough” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be